Hypotensive glaucoma therapy and neuroprotection
Most modern antihypertensive drugs used in the treatment of primary open-angle glaucoma have an indirect neuroprotective effect not only because they reduce intraocular pressure (IOP), but also because of a stimulating effect on the natural metabolic processes in the eye. Researchers and clinicians...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2020-05-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/434 |
| _version_ | 1797878286570749952 |
|---|---|
| author | A. N. Zhuravleva M. V. Zueva |
| author_facet | A. N. Zhuravleva M. V. Zueva |
| author_sort | A. N. Zhuravleva |
| collection | DOAJ |
| description | Most modern antihypertensive drugs used in the treatment of primary open-angle glaucoma have an indirect neuroprotective effect not only because they reduce intraocular pressure (IOP), but also because of a stimulating effect on the natural metabolic processes in the eye. Researchers and clinicians today follow the strategy of compensating IOP, starting from the earliest stages of glaucomatous optic neuropathy (GON), regardless of which drug (generic or original) reduces IOP and which combination of the main active substances this drug has. The need for neuroprotective therapy in clinical practice mainly appears either in the far advanced stages or in cases of progressive loss of visual functions. However, given the multifactorial nature of GON, it is extremely important to add neuroprotective treatment in time, starting from the early stages. Electrophysiological and morphometric studies can provide objective monitoring of neuroprotective therapy. In order to increase the effectiveness of treatment, hypotensive therapy should be supplemented by early use of direct neuroprotectors targeted at oxidative stress, and excitotoxicity and affecting other molecular mechanisms of glaucoma so as the primary events of neurodegeneration could be blocked. |
| first_indexed | 2024-04-10T02:31:23Z |
| format | Article |
| id | doaj.art-552ae8fec14e421481df9522e40cab61 |
| institution | Directory Open Access Journal |
| issn | 2072-0076 2587-5760 |
| language | Russian |
| last_indexed | 2024-04-10T02:31:23Z |
| publishDate | 2020-05-01 |
| publisher | Real Time Ltd |
| record_format | Article |
| series | Российский офтальмологический журнал |
| spelling | doaj.art-552ae8fec14e421481df9522e40cab612023-03-13T07:54:30ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602020-05-01132788210.21516/2072-0076-2020-13-2-78-82287Hypotensive glaucoma therapy and neuroprotectionA. N. Zhuravleva0M. V. Zueva1ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава РоссииФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава РоссииMost modern antihypertensive drugs used in the treatment of primary open-angle glaucoma have an indirect neuroprotective effect not only because they reduce intraocular pressure (IOP), but also because of a stimulating effect on the natural metabolic processes in the eye. Researchers and clinicians today follow the strategy of compensating IOP, starting from the earliest stages of glaucomatous optic neuropathy (GON), regardless of which drug (generic or original) reduces IOP and which combination of the main active substances this drug has. The need for neuroprotective therapy in clinical practice mainly appears either in the far advanced stages or in cases of progressive loss of visual functions. However, given the multifactorial nature of GON, it is extremely important to add neuroprotective treatment in time, starting from the early stages. Electrophysiological and morphometric studies can provide objective monitoring of neuroprotective therapy. In order to increase the effectiveness of treatment, hypotensive therapy should be supplemented by early use of direct neuroprotectors targeted at oxidative stress, and excitotoxicity and affecting other molecular mechanisms of glaucoma so as the primary events of neurodegeneration could be blocked.https://roj.igb.ru/jour/article/view/434глаукомакомпенсация вгдпрямая и непрямая нейропротекциягенерические препаратыэлектрофизиологические исследования |
| spellingShingle | A. N. Zhuravleva M. V. Zueva Hypotensive glaucoma therapy and neuroprotection Российский офтальмологический журнал глаукома компенсация вгд прямая и непрямая нейропротекция генерические препараты электрофизиологические исследования |
| title | Hypotensive glaucoma therapy and neuroprotection |
| title_full | Hypotensive glaucoma therapy and neuroprotection |
| title_fullStr | Hypotensive glaucoma therapy and neuroprotection |
| title_full_unstemmed | Hypotensive glaucoma therapy and neuroprotection |
| title_short | Hypotensive glaucoma therapy and neuroprotection |
| title_sort | hypotensive glaucoma therapy and neuroprotection |
| topic | глаукома компенсация вгд прямая и непрямая нейропротекция генерические препараты электрофизиологические исследования |
| url | https://roj.igb.ru/jour/article/view/434 |
| work_keys_str_mv | AT anzhuravleva hypotensiveglaucomatherapyandneuroprotection AT mvzueva hypotensiveglaucomatherapyandneuroprotection |